MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ
4.460
+0.010
+0.22%
After Hours: 4.532 +0.072 +1.61% 19:15 06/24 EDT
OPEN
4.460
PREV CLOSE
4.450
HIGH
4.519
LOW
4.360
VOLUME
2.91M
TURNOVER
--
52 WEEK HIGH
5.10
52 WEEK LOW
3.040
MARKET CAP
881.02M
P/E (TTM)
5.42
1D
5D
1M
3M
1Y
5Y
1D
Moderna: The Comeback Is Now In Full Swing
Seeking Alpha · 1d ago
Weekly Report: what happened at ABUS last week (0615-0619)?
Weekly Report · 2d ago
Weekly Report: what happened at ABUS last week (0608-0612)?
Weekly Report · 06/15 10:20
Weekly Report: what happened at ABUS last week (0601-0605)?
Weekly Report · 06/08 10:16
Weekly Report: what happened at ABUS last week (0525-0529)?
Weekly Report · 06/01 10:20
Arbutus Biopharma Shareholders Approve New 2026 Incentive Plan
TipRanks · 05/27 21:02
Arbutus Biopharma shareholders approve 2026 omnibus share, incentive plan at annual meeting
PUBT · 05/27 20:04
Weekly Report: what happened at ABUS last week (0518-0522)?
Weekly Report · 05/25 10:24
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Webull offers Arbutus Biopharma Corp stock information, including NASDAQ: ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.